# Amgen Inc. – Consensus ‘buy’ rating and -4.6% Downside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc.consensus-buy-rating-and-4.6-downside-potential/4121166219
- Published: 2024-07-26T13:08:49+01:00
- Author: Charlotte Edwards

**Amgen Inc.** with ticker code (AMGN) have now 23 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges
between $380.00 and $170.00 calculating the average target price we see $320.24.
Given that the stocks previous close was at $335.61 this is indicating there is 
a potential downside of -4.6%. The day 50 moving average is $314.00 and the 200 
day moving average is $290.22. The market cap for the company is 179.33B. The stock
price is currently at: $334.30 USD

 The potential market cap would be $171,117,397,167 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 47.83, revenue per share of $55.15
and a 4.88% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on: